Clinical trial NCT03817931: Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
Official title: Higher Neural and Cognitive Changes Following Anticholinergic Versus Beta 3 Agonist Versus Placebo Treatments in Female Patients With Overactive Bladder: a Multicenter Randomized Controlled Pilot Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Overactive Bladder
Dementia
Lower Urinary Tract Symptoms
Incontinence, Urge
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
Collaborators: name: The Methodist Hospital Research Institute
name: International Urogynecological Association
First posted: 2019-01-28
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Permuted block stratified by recruitment site
Primary purpose: PREVENTION

Brief summary: Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded intervention for 30 days.

Detailed description: Women presenting to the urology clinic with complaints of urinary urgency, frequency in the absence of urinary tract infection or other obvious pathology will be screened for inclusion/exclusion criteria. Qualifying subjects will be consented.

Baseline health information, bladder symptom questionnaires (Overactive Bladder-questionnaire(OABq), Patient Perception of Bladder Condition (PPBC)), Personal Health Questionnaire-9 (PHQ-9),Hamilton Anxiety Rating Scale (HAM-A), Montreal cognitive assessment (MoCA) will be given. If baseline depression (PHQ-9 score 15 or greater),dementia (MoCA score 25 or less), anxiety (HAM-A score 25-30) are noted the subject is excluded. 15 patients will be recruited from Baylor Scott \& White Health Urology clinic, and 15 patients will be recruited from Houston Methodist Urology clinic.

They will schedule a date within 1 month for the Rey Auditory Verbal Learning Test (RAVLT) and brain functional MRI (fMRI). RAVLT test is performed, followed by resting state fMRI and memory task during fMRI. Vials of medication will be distributed. Vials will be labeled 1-30 and will contain 30 tablets each. The anticholinergic and beta-3 agonist tablets will be encapsulated to look identical to the placebo tablet. Subjects will be reimbursed at this visit. fMRI images at baseline and post-intervention will be analyzed by a radiologist for incidental findings.

One week and two weeks after initiating their tablets, phone interviews will inquire about pill count, side effects, and any new medications. Follow up testing date will be scheduled during the call. The same questions will be repeated at completion of the tablets (30 days after initiation).

At completion of the tablets, subjects return to Houston Methodist for repeat RAVLT and fMRI. Subjects will be reimbursed the other half of their compensation at this visit.

An expert physicist will analyze the BOLD signal intensity and FC pattern in a priori selected regions of interest before and after interventions.

Eligibility criteria: Inclusion Criteria:

* Female patients of age 50 to 90 years old with OAB as defined by the International Continence Society (Urgency with or without urge incontinence, usually with frequency and nocturia in the absence of urinary tract infection or other obvious pathology) who report that symptoms cause moderate problems using the PPBC.
* English-speaking and able to consent

Exclusion Criteria:

* Males are excluded to eliminate prostate pathology and urethral strictures, as well as possible bias of gender differences on fMRI.
* Subjects with moderately severe or severe depression (screening score of 15 or more) on the Personal Health Questionnaire-9 (PHQ-9)
* Subjects with moderate to severe anxiety (screening score 25-30) on the Hamilton Anxiety Rating Scale (HAM-A)
* A screening score indicating below normal cognitive function at baseline (score of 25 or less) on the montreal cognitive assessment.
* Subjects with neurologic disorders, dementia, prior cerebrovascular accident, neurogenic bladder or post-void residual greater than 250 mL
* Anticholinergics for OAB or beta 3 agonists use for treatment of OAB in the preceding six months prior to enrollment
* Pregnant or planning to become pregnant in the next six months, or current breastfeeding
* The inability to undergo MRI

Primary outcomes:
measure: Functional connectivity on MRI
timeFrame: 29 +/-1 days
measure: Resting state blood oxygenation level dependent (BOLD)changes
timeFrame: 29 +/-1 days
measure: Diffusion tensor imaging
timeFrame: 29 +/-1 days
Secondary outcomes:
measure: Score on Rey Auditory Verbal Learning Test (RAVLT)
timeFrame: 30 days
measure: Overactive bladder questionnaire (OAB-q)
timeFrame: 30 days
measure: Patient Perception of Bladder Condition (PPBC)
timeFrame: 30 days
Other outcomes:
Locations:
city: Houston
country: United States
facility: Houston Methodist Hospital
state: Texas
city: Temple
country: United States
facility: Baylor Scott and White Health
state: Texas
Study officials:
affiliation: Baylor Scott and White Health
name: Jill Danford, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: The Methodist Hospital Research Institute
name: Rose Khavari, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Baylor Scott and White Health
name: Rachel High, DO
role: PRINCIPAL_INVESTIGATOR
References: